Clinical Trial Update: Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sintilimab plus anlotinib as second- or later-line therapy for extensive-stage small cell lung cancer that progressed after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer Extensive Stage

Drugs mentioned

• Anlotinib (anlotinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: First Affiliated Hospital of Wannan Medical College | Conditions: Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy | Phase 2 | Status: NOT_YET_RECRUITING